Biomarin Pharmaceutical (WBO:BMRN) Total Liabilities : €1,271 Mil (As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Biomarin Pharmaceutical Total Liabilities?

Biomarin Pharmaceutical's Total Liabilities for the quarter that ended in Dec. 2024 was €1,271 Mil.

Biomarin Pharmaceutical's quarterly Total Liabilities declined from Jun. 2024 (€1,654.38 Mil) to Sep. 2024 (€1,295.46 Mil) and declined from Sep. 2024 (€1,295.46 Mil) to Dec. 2024 (€1,271.06 Mil).

Biomarin Pharmaceutical's annual Total Liabilities increased from Dec. 2022 (€1,672.69 Mil) to Dec. 2023 (€1,733.18 Mil) but then declined from Dec. 2023 (€1,733.18 Mil) to Dec. 2024 (€1,271.06 Mil).

Biomarin Pharmaceutical Total Liabilities Historical Data

The historical data trend for Biomarin Pharmaceutical's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Total Liabilities Chart

Biomarin Pharmaceutical Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

1,431.94

1,539.11

1,672.69

1,733.18

1,271.06

Biomarin Pharmaceutical Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Liabilities	Get a 7-Day Free Trial															1,733.18	1,654.95	1,654.38	1,295.46	1,271.06

Biomarin Pharmaceutical Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Biomarin Pharmaceutical's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	579.674	+	(568.357	+	123.026
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	1,271

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	6674.438	-	5403.38
	=	1,271

Biomarin Pharmaceutical's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	579.674	+	(568.357	+	123.026
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	1,271

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	6674.438	-	5403.38
	=	1,271

Biomarin Pharmaceutical Total Liabilities Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Biomarin Pharmaceutical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (WBO:BMRN) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

BMRN:USA BMRN:Mexico 1BMRN:Italy 0HNC:UK BM8:Germany BM8:Germany B1MR34:Brazil

Address

770 Lindaro Street, San Rafael, CA, USA, 94901

Website

https://www.biomarin.com

BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.